APA (7th ed.) Citation

Herold, K. C., Gitelman, S. E., Gottlieb, P. A., Knecht, L. A., Raymond, R., & Ramos, E. L. (2023). Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function. Diabetes care, 46(10), 1848-1856. https://doi.org/10.2337/dc23-0675

Chicago Style (17th ed.) Citation

Herold, Kevan C., Stephen E. Gitelman, Peter A. Gottlieb, Laura A. Knecht, Ralph Raymond, and Eleanor L. Ramos. "Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function." Diabetes Care 46, no. 10 (2023): 1848-1856. https://doi.org/10.2337/dc23-0675.

MLA (9th ed.) Citation

Herold, Kevan C., et al. "Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function." Diabetes Care, vol. 46, no. 10, 2023, pp. 1848-1856, https://doi.org/10.2337/dc23-0675.